Celsion Names BPH Treatment System - Prolieve.

Business Editors/Health/Medical Writers

COLUMBIA, Md.--(BUSINESS WIRE)--Feb. 13, 2004

Celsion Corporation (AMEX:CLN) today announced that it is naming its Transurethral Microwave Thermotherapy System, which is currently under PMA review by the FDA, the Prolieve(TM) Thermodilitation system. Upon approval by the FDA, the system, formerly known as the Microfocus(TM) BPH 800 Microwave Urethroplasty(TM) system, will be distributed and marketed by Boston Scientific Corporation.

Dan Reale, Celsion's Executive Vice President, said, "The Prolieve Thermodilitation name was chosen as it describes our unique mechanism of action in which BPH symptoms are relieved through the dual techniques of applying heat to the prostate while simultaneously dilating the urethra with a balloon catheter."

Benign Prostatic Hyperplasia (BPH), otherwise known as enlarged prostate, affects men as they age, resulting in frequent urination and other difficulties. Current treatments, which include drug therapy and minimally invasive treatments, are such that seven million of the nine million American men affected choose not to be treated.

In January 2003, Celsion entered into a strategic alliance with Boston Scientific Corporation (NYSE:BSX) in which Boston Scientific will initially distribute the Prolieve Thermodilitation system in the United States.

About Celsion: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of treatment systems for cancer and other diseases using focused-heat energy, either administered alone, or in combination with other therapeutic devices, heat activated genes and heat activated drugs.

In January 2003, Celsion entered into a strategic alliance with Boston Scientific Corporation (NYSE:BSX) in which Boston Scientific will initially distribute Celsion's BPH product worldwide. Boston Scientific currently owns approximately 6% of Celsion's outstanding stock.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.